MovDisordV3, PubMed, Corpus, bibRecord, 003E87

The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.

Identifieur interne : 003E87 ( PubMed/Corpus ); précédent : 003E86; suivant : 003E88

The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.

Auteurs : H A Hana Asi ; G. Kaptanoglu ; H A Sahin ; M. Emre

Source :

Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2000.

RBID : pubmed:11009218

English descriptors

KwdEn :
- Adult, Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Dopamine Agents (administration & dosage), Dopamine Agents (therapeutic use), Dose-Response Relationship, Drug, Drug Therapy, Combination, Dyskinesia, Drug-Induced (etiology), Dyskinesia, Drug-Induced (prevention & control), Excitatory Amino Acid Antagonists (administration & dosage), Excitatory Amino Acid Antagonists (therapeutic use), Humans, Levodopa (pharmacology), Levodopa (therapeutic use), Male, Memantine (administration & dosage), Memantine (therapeutic use), N-Methylaspartate (antagonists & inhibitors), Parkinsonian Disorders (complications), Parkinsonian Disorders (drug therapy), Treatment Outcome.
MESH :
- chemical , administration & dosage : Dopamine Agents, Excitatory Amino Acid Antagonists, Memantine.
- chemical , antagonists & inhibitors : N-Methylaspartate.
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agents, Excitatory Amino Acid Antagonists, Levodopa, Memantine.
- complications : Parkinsonian Disorders.
- drug therapy : Parkinsonian Disorders.
- etiology : Dyskinesia, Drug-Induced.
- prevention & control : Dyskinesia, Drug-Induced.
- Adult, Dose-Response Relationship, Drug, Drug Therapy, Combination, Humans, Male, Treatment Outcome.

PubMed: 11009218

Links to Exploration step

pubmed:11009218

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.</title>
<author><name sortKey="Hana Asi, H A" sort="Hana Asi, H A" uniqKey="Hana Asi H" first="H A" last="Hana Asi">H A Hana Asi</name>
<affiliation><nlm:affiliation>Istanbul University, Istanbul Medical Faculty, Department of Neurology, Capa, Turkey.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kaptanoglu, G" sort="Kaptanoglu, G" uniqKey="Kaptanoglu G" first="G" last="Kaptanoglu">G. Kaptanoglu</name>
</author>
<author><name sortKey="Sahin, H A" sort="Sahin, H A" uniqKey="Sahin H" first="H A" last="Sahin">H A Sahin</name>
</author>
<author><name sortKey="Emre, M" sort="Emre, M" uniqKey="Emre M" first="M" last="Emre">M. Emre</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2000">2000</date>
<idno type="RBID">pubmed:11009218</idno>
<idno type="pmid">11009218</idno>
<idno type="wicri:Area/PubMed/Corpus">003E87</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.</title>
<author><name sortKey="Hana Asi, H A" sort="Hana Asi, H A" uniqKey="Hana Asi H" first="H A" last="Hana Asi">H A Hana Asi</name>
<affiliation><nlm:affiliation>Istanbul University, Istanbul Medical Faculty, Department of Neurology, Capa, Turkey.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Kaptanoglu, G" sort="Kaptanoglu, G" uniqKey="Kaptanoglu G" first="G" last="Kaptanoglu">G. Kaptanoglu</name>
</author>
<author><name sortKey="Sahin, H A" sort="Sahin, H A" uniqKey="Sahin H" first="H A" last="Sahin">H A Sahin</name>
</author>
<author><name sortKey="Emre, M" sort="Emre, M" uniqKey="Emre M" first="M" last="Emre">M. Emre</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2000" type="published">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Dopamine Agents (administration & dosage)</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Therapy, Combination</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Dyskinesia, Drug-Induced (prevention & control)</term>
<term>Excitatory Amino Acid Antagonists (administration & dosage)</term>
<term>Excitatory Amino Acid Antagonists (therapeutic use)</term>
<term>Humans</term>
<term>Levodopa (pharmacology)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Memantine (administration & dosage)</term>
<term>Memantine (therapeutic use)</term>
<term>N-Methylaspartate (antagonists & inhibitors)</term>
<term>Parkinsonian Disorders (complications)</term>
<term>Parkinsonian Disorders (drug therapy)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dopamine Agents</term>
<term>Excitatory Amino Acid Antagonists</term>
<term>Memantine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>N-Methylaspartate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agents</term>
<term>Excitatory Amino Acid Antagonists</term>
<term>Levodopa</term>
<term>Memantine</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Male</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11009218</PMID>
<DateCreated><Year>2001</Year>
<Month>01</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted><Year>2001</Year>
<Month>01</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>15</Volume>
<Issue>5</Issue>
<PubDate><Year>2000</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.</ArticleTitle>
<Pagination><MedlinePgn>1016-7</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hanağasi</LastName>
<ForeName>H A</ForeName>
<Initials>HA</Initials>
<AffiliationInfo><Affiliation>Istanbul University, Istanbul Medical Faculty, Department of Neurology, Capa, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kaptanoglu</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sahin</LastName>
<ForeName>H A</ForeName>
<Initials>HA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Emre</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>UNITED STATES</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>6384-92-5</RegistryNumber>
<NameOfSubstance UI="D016202">N-Methylaspartate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber>
<NameOfSubstance UI="D008559">Memantine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D015259">Dopamine Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018691">Excitatory Amino Acid Antagonists</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008559">Memantine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016202">N-Methylaspartate</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D020734">Parkinsonian Disorders</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year>
<Month>9</Month>
<Day>29</Day>
<Hour>11</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2001</Year>
<Month>2</Month>
<Day>28</Day>
<Hour>10</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2000</Year>
<Month>9</Month>
<Day>29</Day>
<Hour>11</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">11009218</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E87 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003E87 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:11009218
   |texte=   The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:11009218" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.

The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.

Source :

English descriptors

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki